These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 31759358)
21. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230 [TBL] [Abstract][Full Text] [Related]
22. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators. Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098 [TBL] [Abstract][Full Text] [Related]
23. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LG; Masucci M; Pramanik A; Selivanova G Nat Med; 2004 Dec; 10(12):1321-8. PubMed ID: 15558054 [TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557 [TBL] [Abstract][Full Text] [Related]
26. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway. Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768 [TBL] [Abstract][Full Text] [Related]
27. MDM2 as a target for ellagic acid‑mediated suppression of prostate cancer cells in vitro. Mohammed Saleem YI; Selim MI Oncol Rep; 2020 Sep; 44(3):1255-1265. PubMed ID: 32705219 [TBL] [Abstract][Full Text] [Related]
28. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Ray RM; Bhattacharya S; Johnson LR Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030 [TBL] [Abstract][Full Text] [Related]
29. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer. Roh JL; Park JY; Kim EH Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507 [TBL] [Abstract][Full Text] [Related]
30. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Saha MN; Jiang H; Mukai A; Chang H Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913 [TBL] [Abstract][Full Text] [Related]
31. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems. Shin D; Kim EH; Lee J; Roh JL Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730 [TBL] [Abstract][Full Text] [Related]
32. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Wang H; Yu D; Agrawal S; Zhang R Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324 [TBL] [Abstract][Full Text] [Related]
33. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984 [TBL] [Abstract][Full Text] [Related]
34. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Cheok CF; Dey A; Lane DP Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259 [TBL] [Abstract][Full Text] [Related]
35. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204 [TBL] [Abstract][Full Text] [Related]
36. Overexpression of CCDC69 activates p14 Cui L; Zhou F; Chen C; Wang CC J Ovarian Res; 2019 Jan; 12(1):4. PubMed ID: 30651135 [TBL] [Abstract][Full Text] [Related]
37. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. Davaadelger B; Shen H; Maki CG PLoS One; 2014; 9(11):e110844. PubMed ID: 25380055 [TBL] [Abstract][Full Text] [Related]
38. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148 [TBL] [Abstract][Full Text] [Related]
39. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity. Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135 [TBL] [Abstract][Full Text] [Related]
40. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]